semaglutide and non alcoholic fatty liver disease Non-alcoholic disease: causes, diagnosis, cardiometabolic consequences, treatment strategies semaglutide and non alcoholic fatty

A.CoveyM.LevisonS

Click here to learn more or call our NovoCare Obesity and Bridge Support team at 18888093942, MondayFriday, 8 am8 pm ET

Wise Dr

doi: 10.3389/fphar.2025.1613610 Received 17 April 2025 Accepted 21 August 2025 Published 19 September 2025 Volume 16 - 2025 Edited by Karuna Rasineni, University of Nebraska Medical Center, United States Reviewed by Lai San Tham, Eli Lilly, United States Ligang Liu, The Ohio State University, United States Marcelo Adrian Estrin, Interamerican Open University, Argentina Updates Copyright 2025 Xie, Yang, Deng, Liu, Xu and He

(35447602) neuroimaging in acute hyperammonemic encephalopathy general comments Neuroimaging may be normal this doesnt exclude hyperammonemia

Also, the efficacy and safety of tirzepatide may have a wider perspective for its use beyond patients with T2DM or obesity [9, 10]